Small study aims to personalize drug dosing for young cancer patients

NCT ID NCT06383338

Recruiting now Knowledge-focused Sponsor: Murdoch Childrens Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at how young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain medications. Researchers will give tiny, non-therapeutic doses of two common drugs (omeprazole and dextromethorphan) and measure how they are broken down in the body. The goal is to see if this approach is acceptable and feasible, which could lead to more personalized medicine in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omeprazole and dextromethorphan (probe drugs to measure metabolism)
What this could lead to: If successful, this could pave the way for more personalized dosing of cancer and supportive care drugs in children and young adults with lymphoma.
What could go wrong: This is a very small, early feasibility study with only 10 participants. It is not designed to test treatment effectiveness, only whether the study procedures are acceptable and doable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.